Home LiteratureArticle Details
PMID: 19960244 Published · ppublish English

Subtypes of familial breast tumours revealed by expression and copy number profiling.

Breast cancer research and treatment ·Vol. 123 ·No. 3 ·2011-01-14

Waddell Nic, Arnold Jeremy, Cocciardi Sibylle, da Silva Leonard, Marsh Anna, Riley Joan, Johnstone Cameron N, Orloff Mohammed, Assie Guillaume, Eng Charis, Reid Lynne, Keith Patricia, Yan Max, Fox Stephen, Devilee Peter, Godwin Andrew K, Hogervorst Frans B L, Couch Fergus, , Grimmond Sean, Flanagan James M, Khanna Kumkum, Simpson Peter T, Lakhani Sunil R, Chenevix-Trench Georgia

Abstract

Extensive expression profiling studies have shown that sporadic breast cancer is composed of five clinically relevant molecular subtypes. However, although BRCA1-related tumours are known to be predominantly basal-like, there are few published data on other classes of familial breast tumours. We analysed a cohort of 75 BRCA1, BRCA2 and non-BRCA1/2 breast tumours by gene expression profiling and found that 74% BRCA1 tumours were basal-like, 73% of BRCA2 tumours were luminal A or B, and 52% non-BRCA1/2 tumours were luminal A. Thirty-four tumours were also analysed by single nucleotide polymorphism-comparative genomic hybridization (SNP-CGH) arrays. Copy number data could predict whether a tumour was basal-like or luminal with high accuracy, but could not predict its mutation class. Basal-like BRCA1 and basal-like non-BRCA1 tumours were very similar, and contained the highest number of chromosome aberrations. We identified regions of frequent gain containing potential driver genes in the basal (8q and 12p) and luminal A tumours (1q and 17q). Regions of homozygous loss associated with decreased expression of potential tumour suppressor genes were also detected, including in basal tumours (5q and 9p), and basal and luminal tumours (10q). This study highlights the heterogeneity of familial tumours and the clinical consequences for treatment and prognosis.

Article Info
Journal
Breast cancer research and treatment
Abbr.
Breast Cancer Res Treat
Published
2011-01-14
Indexed
2010-09-16
Updated
2014-09-12
Language
English
Country/Region
Netherlands
NLM ID
8111104
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com